Interaction between hepatokines and metabolic diseases

Yi Chuan. 2022 Oct 20;44(10):853-866. doi: 10.16288/j.yczz.22-218.


Metabolic diseases are broadly defined as diseases caused by problems in metabolic function, including central obesity, insulin resistance, lipid glucose abnormalities, and elevated blood pressure. As an important metabolic organ, the liver plays a key role in regulating many physiological processes such as systemic glucose and lipid metabolism. Numerous studies in recent years have shown that the liver can synthesize and secrete a variety of hepatokines, including FGF21, Fetuin-A and ANGPTL8, which regulate the metabolism in an autocrine/paracrine manner. Intervention of hepatokines expression may contribute to the prevention, diagnosis and treatment of metabolic diseases. However, further studies are needed to be investigated as the mechanism of hepatokines and metabolic homeostasis is still elusive. In this review, we summarize the relationships between hepatokines and metabolic diseases in order to provide new strategies for the treatment of metabolic diseases.


Keywords: diagnosis and therapy; hepatokines; metabolic diseases.

Publication types

  • Review

MeSH terms

  • Angiopoietin-like Proteins / metabolism
  • Glucose / metabolism
  • Humans
  • Insulin Resistance* / physiology
  • Liver / metabolism
  • Metabolic Diseases* / metabolism
  • Obesity
  • Peptide Hormones* / metabolism


  • Glucose
  • ANGPTL8 protein, human
  • Angiopoietin-like Proteins
  • Peptide Hormones